MARKET

BGNE

BGNE

BeiGene
NASDAQ

Real-time Quotes | Nasdaq Last Sale

123.11
-2.28
-1.82%
After Hours: 123.11 0 0.00% 18:07 03/31 EDT
OPEN
124.31
PREV CLOSE
125.39
HIGH
126.65
LOW
122.52
VOLUME
356.58K
TURNOVER
--
52 WEEK HIGH
210.35
52 WEEK LOW
113.01
MARKET CAP
9.51B
P/E (TTM)
-7.3303
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of BGNE and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 15 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average BGNE stock price target is 200.11 with a high estimate of 232.00 and a low estimate of 165.00.

EPS

BGNE News

More
  • ROSEN, A HIGHLY RANKED FIRM, Continues to Investigate Securities Claims Against BeiGene, Ltd.
  • Business Wire · 5d ago
  • BeiGene reports Abraxane shortage in China
  • seekingalpha · 6d ago
  • BeiGene Announces Supply Update for ABRAXANE® in China
  • GlobeNewswire · 6d ago
  • Hedge Funds Are Betting On BeiGene, Ltd. (BGNE)
  • Insider Monkey · 03/19 22:09

Industry

Biotechnology & Medical Research
-0.26%
Pharmaceuticals & Medical Research
-0.17%

Hot Stocks

Symbol
Price
%Change

About BGNE

BeiGene, Ltd. is principally engaged in biopharmaceutical business. The Company is mainly engaged in the research and development, production and sales of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company's main products include Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317) and Pamiparib (BGB-290).
More

Webull offers kinds of Beigene Ltd (ADR) stock information, including NASDAQ:BGNE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BGNE stock news, and many more online research tools to help you make informed decisions.